MHRA issues contraception warning for women using weight-loss injections
Women prescribed GLP-1 weight-loss medications urged to use effective contraception as MHRA highlights reproductive health concerns
The UK’s medicines regulator has issued new safety guidance for women taking weight-loss injections, warning that some medications may interfere with oral contraceptives and are not safe for use during pregnancy or breastfeeding.
The Medicines and Healthcare products Regulatory Agency (MHRA) said that women using tirzepatide should also use barrier methods such as condoms if they rely on oral contraception. The warning follows concerns that an increasing number of women may be accessing these drugs through unregulated channels and may not be fully informed of the risks.
GLP-1 receptor agonists — including tirzepatide, semaglutide and liraglutide — are not suitable for use during pregnancy, while trying to conceive or when breastfeeding. Women who become pregnant while taking these medicines should stop treatment immediately, the MHRA said, adding that in some cases, contraception should be continued for up to two months after stopping the medication.
“There is not enough safety data to know whether taking GLP-1 receptor agonists during pregnancy could harm the baby,” the agency stated. “These drugs should only be used under the supervision of a healthcare professional.”
The MHRA has received over 40 reports of pregnancy in women using GLP-1 medications, including 26 cases involving tirzepatide and eight involving semaglutide. Nine reports were linked to liraglutide. While the agency cautioned that these Yellow Card reports do not confirm a causal relationship, they are being closely monitored.
The latest guidance also reiterates that weight-loss injections should not be obtained through unregulated sources such as beauty salons or social media. Use without medical supervision could increase the risk of complications, including unintended pregnancy and adverse effects such as acute pancreatitis.
Dr Alison Cave, Chief Safety Officer at the MHRA, said: “Patients should always consult a qualified healthcare professional and read the patient information leaflet before starting treatment. Gastrointestinal side effects such as vomiting and diarrhoea may impair absorption of oral contraceptives, increasing the risk of unintended pregnancy.
Healthcare professionals are encouraged to discuss these risks with individuals and ensure that women of childbearing age are fully informed of the reproductive safety considerations associated with GLP-1 weight-loss therapies.